Dyadic International Inc, a biotech firm specializing in microbial protein production and alternative proteins, demonstrated progress in reducing operating losses in FY2025 despite continued net losses of approximately $7.4 million [F1]. The company maintains liquidity with a current ratio of 2.68 and cash and equivalents of $4.6 million as of year-end 2025 [F1]. Recent grant funding supports expansion into antibody development, complementing its microbial protein platform efforts [N1][N2]. However, Dyadic faces ongoing challenges meeting Nasdaq's minimum bid price and market value listing requirements, having recently regained compliance but with a June 2026 deadline for sustained adherence [S1][S2][S4]. Capital raising through an At-The-Market equity program supplements financing needs amid no recent dividends or share repurchases [S17][F1].